Comunicati Stampa
Salute e Benessere

Avance Clinical Showcases Early Phase Expertise and the Australian Advantage for EU Biotechs at BIO-Europe Vienna

Helping European Biotechs Accelerate Early Phase Success With Faster Timelines, Lower Costs, and Globally Accepted Data Avance Clinical, the largest premium full-service Australian headquartered CRO with more than 30 years of early phase expertise, is highlighting its Early Phase Center of Excellence for Biotechs and the well-established Australian Advantage to European biotechs ahead ofBIO-Europe in Vienna, November 3-5, 2025.European biotechs under increasing investor and...
ADELAIDE, (informazione.news - comunicati stampa - salute e benessere)

Avance Clinical, the largest premium full-service Australian headquartered CRO with more than 30 years of early phase expertise, is highlighting its Early Phase Center of Excellence for Biotechs and the well-established Australian Advantage to European biotechs ahead of BIO-Europe in Vienna, November 3-5, 2025.

European biotechs under increasing investor and regulatory pressure are turning to Avance Clinical’s proven Australian pathway to achieve first-in-human (FIH) and early proof-of-concept studies with:

“EU biotechs are often surprised to learn just how efficient Australia is for early phase research,” said Mark Harvill , CEO of Avance Clinical . “Our new Early Phase Center of Excellence for Biotechs underscores our commitment to scientific rigor, innovation, and helping sponsors reach critical milestones faster — without compromising quality.”

Avance Clinical has guided more than 710 emerging biotechs across 250+ therapeutic indications , supported by in-house scientific and regulatory affairs expertise, and best-in-class clinical operations. Its dedicated Early Phase Center of Excellence for Biotechs was designed specifically to meet the needs of international biotech sponsors navigating complex first-in-human and early development studies.

“With growing competition in biotech, speed and quality in early development are critical,” said Ben Edwards , Chief Operating Officer of Avance Clinical. “By combining the Australian Advantage, which offers up to 43.5% Australian Government R&D tax rebate, with our deep early phase expertise, EU sponsors can de-risk their programs and maintain capital efficiency while advancing quickly to global markets.”

Meet Avance Clinical at BIO-Europe Vienna

European biotechs attending BIO-Europe 2025 are invited to meet with Liahna Toy , Vice President, Commercial Business Development , and Dewald Jacobs , Director of Business Development , at Booth #C185 at the Vienna Congress & Convention Center (Messe Wien), November 3-5, 2025.

This is a unique opportunity for EU sponsors to discuss how Avance Clinical’s early phase expertise and the Australian Advantage can accelerate development pipelines.

Book a Meeting Now

About Avance Clinical

Avance Clinical is the largest premium full-service Australian headquartered CRO delivering high-quality clinical trials in Australia, New Zealand, Asia, North America, and Europe for international biotechs. The company has won multiple Frost & Sullivan CRO Market Leadership and Customer Value Leadership Awards.

With over 30 years of experience and cross-therapeutic expertise in more than 250 indications, Avance Clinical provides services from pre-clinical to late-phase trials, supported by best-in-class regulatory, clinical, and operational teams.

Find out more:

CONTACT :
Gabe Martinez
Director Content, Media, & PR
308-237-5567
Pr@scorrmarketing.com

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/6bdfcdd6-822b-4af9-aa9a-832fc449ca24


Per maggiori informazioni
Ufficio Stampa
 Nasdaq GlobeNewswire (Leggi tutti i comunicati)
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti
Allegati
Non disponibili